Literature DB >> 33169684

Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer's disease.

Periyanaina Kesika1, Natarajan Suganthy2, Bhagavathi Sundaram Sivamaruthi1, Chaiyavat Chaiyasut3.   

Abstract

Gut microbiota represents a diverse and dynamic population of microorganisms harboring the gastrointestinal tract, which influences the host health and disease. Gut microbiota communicates with the brain and vice versa through complex bidirectional communication systems - the gut-brain axis, which integrates the peripheral intestinal function with emotional and cognitive brain centers via neuro-immuno-endocrine mediators. Aging alters the gut microbial population, which not only leads to gastrointestinal disturbances but also causes central nervous system (CNS) disorders such as dementia. Alzheimer's disease (AD) is the most common form of dementia affecting the older person, characterized by beta-amyloid (Aβ) plaques and neurofibrillary tangles leading to the cognitive deficit and memory impairment. Multiple experimental and clinical studies revealed the role of gut microbiota in host cognition, and its dysbiosis associated with aging leads to neurodegeneration. Gut microbial dysbiosis leads to the secretion of amyloid and lipopolysaccharides (LPS), which disturbs the gastrointestinal permeability and blood-brain barrier. Thereby modulates the inflammatory signaling pathway promoting neuroinflammation, neuronal injury, and ultimately leading to neuronal death in AD. A recent study revealed the antimicrobial property of Aβ peptide as an innate immune response against pathogenic microbes. Another study showed that bacterial amyloid shares molecular mimicry with Aβ peptide, which elicits misfolding and aggregation of Aβ peptide, it's seeding, and propagation through the gut-brain axis followed by microglial cell activation. As aging together with poor diet and gut-derived inflammatory response due to dysbiosis contributes to the pathogenesis of AD, modification of gut microbial composition by uptake of probiotic-rich food can act as a preventive/therapeutic option for AD. The objective of the present review is to summarize the recent findings on the role of gut microbiota in the development of AD. Understanding the relationship between gut microbiota and CNS will help identify novel therapeutic strategies, especially probiotic-based supplementation, for the treatment of AD.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid protein; Gut microbiome; Inflammation; Lipopolysaccharides

Year:  2020        PMID: 33169684     DOI: 10.1016/j.lfs.2020.118627

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  57 in total

Review 1.  Unravelling the potential of gut microbiota in sustaining brain health and their current prospective towards development of neurotherapeutics.

Authors:  Ankita Banerjee; Lilesh Kumar Pradhan; Santosh Chauhan; Pradyumna Kumar Sahoo; Kautilya Kumar Jena; Nishant Ranjan Chauhan; Saroj Kumar Das
Journal:  Arch Microbiol       Date:  2021-03-24       Impact factor: 2.552

Review 2.  N6-methyladenosine and Neurological Diseases.

Authors:  Nan Zhang; Chunhong Ding; Yuxin Zuo; Yu Peng; Lielian Zuo
Journal:  Mol Neurobiol       Date:  2022-01-15       Impact factor: 5.590

Review 3.  Overlapping Mechanisms of Action of Brain-Active Bacteria and Bacterial Metabolites in the Pathogenesis of Common Brain Diseases.

Authors:  Tanja Patricia Eicher; M Hasan Mohajeri
Journal:  Nutrients       Date:  2022-06-27       Impact factor: 6.706

4.  Repurposing of intestinal defensins as multi-target, dual-function amyloid inhibitors via cross-seeding.

Authors:  Yijing Tang; Dong Zhang; Xiong Gong; Jie Zheng
Journal:  Chem Sci       Date:  2022-05-20       Impact factor: 9.969

Review 5.  Modifying the diet and gut microbiota to prevent and manage neurodegenerative diseases.

Authors:  Ellen J Gates; Anna K Bernath; Andis Klegeris
Journal:  Rev Neurosci       Date:  2022-03-21       Impact factor: 4.703

6.  Probiotics ameliorates LPS induced neuroinflammation injury on Aβ 1-42, APP, γ-β secretase and BDNF levels in maternal gut microbiota and fetal neurodevelopment processes.

Authors:  Fatih Kar; Ceyhan Hacioglu; Ezgi Kar; Dilek Burukoglu Donmez; Güngör Kanbak
Journal:  Metab Brain Dis       Date:  2022-03-21       Impact factor: 3.655

Review 7.  Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer's Disease.

Authors:  Tamas Fulop; Shreyansh Tripathi; Serafim Rodrigues; Mathieu Desroches; Ton Bunt; Arnold Eiser; Francois Bernier; Pascale B Beauregard; Annelise E Barron; Abdelouahed Khalil; Adam Plotka; Katsuiku Hirokawa; Anis Larbi; Christian Bocti; Benoit Laurent; Eric H Frost; Jacek M Witkowski
Journal:  Neuropsychiatr Dis Treat       Date:  2021-05-04       Impact factor: 2.570

Review 8.  Crosstalk between Gut and Brain in Alzheimer's Disease: The Role of Gut Microbiota Modulation Strategies.

Authors:  Umair Shabbir; Muhammad Sajid Arshad; Aysha Sameen; Deog-Hwan Oh
Journal:  Nutrients       Date:  2021-02-21       Impact factor: 5.717

Review 9.  Neuroinflammation in Alzheimer's Disease.

Authors:  Isaac G Onyango; Gretsen V Jauregui; Mária Čarná; James P Bennett; Gorazd B Stokin
Journal:  Biomedicines       Date:  2021-05-07

Review 10.  Some Candidate Drugs for Pharmacotherapy of Alzheimer's Disease.

Authors:  Barbara Miziak; Barbara Błaszczyk; Stanisław J Czuczwar
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.